Clinical Trials Logo

Clinical Trial Details — Status: Recruiting

Administrative data

NCT number NCT03215199
Other study ID # HREBA.CC-17-0160
Secondary ID
Status Recruiting
Phase N/A
First received
Last updated
Start date September 1, 2017
Est. completion date June 13, 2024

Study information

Verified date July 2023
Source University of Alberta
Contact Brittany Barber
Phone 6464459592
Email brittanybarber0@gmail.com
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

This is a randomized controlled trial comparing a web-based psychosocial screening application to usual care in a cohort of surgically-treated head and neck cancer patients to determine its efficacy in monitoring depression and distress, and prompting necessary psychiatry/psychology referrals. In addition, treatment adherence, rehabilitation and return to work, primary care utilization, and survival will be monitored.


Description:

This is a randomized controlled trial comparing a web-based psychosocial screening application to usual care in a cohort of surgically-treated head and neck cancer patients. This study will utilize a web-based application available on desktop or laptop computers, and smartphones. The application involves monitoring using the NCCN Distress Thermometer Score, the Quick Inventory of Depressive Symptomatology-Self Report (QIDS-SR) score, and the Head and Neck Research Network (HNRN-33), a patient-reported, validated functional outcomes score. These assessments will be completed at baseline, 2 weeks postoperatively, and monthly thereafter until 12 months. Patients will have the option of filling out questionnaires more frequently if desired. This web-based application, the NAPT App, will allow patients to alert the treatment team of their current state of mood or distress. Automatic alerts will be sent to the team if a Distress Score of /=11, or suicidal ideation are expressed in the application. The study duration will be 12 months with a primary endpoint of 6 months. Our primary outcome will be NCCN Distress Thermometer Score at 6 months, with secondary outcomes of the QIDS and HNRN-33 functional scores at 6 and 12 months. Additional outcomes assessed will pertain to completion of adjuvant therapy, weight maintenance, rehabilitation and return to work, and survival. Health services delivery outcomes, such as primary care visits, emergency department visits, hospitalizations, and narcotic use will also be evaluated.


Recruitment information / eligibility

Status Recruiting
Enrollment 50
Est. completion date June 13, 2024
Est. primary completion date June 13, 2024
Accepts healthy volunteers No
Gender All
Age group 18 Years and older
Eligibility Inclusion Criteria: - 18 years - New (non-recurrent) head and neck cancer - Primary surgical treatment Exclusion Criteria: - <18 years - Recurrent head and neck cancer - Previous chemotherapy or radiation therapy - History of psychiatric or psychologic illness - History of previous cancers or cancer distress

Study Design


Related Conditions & MeSH terms


Intervention

Other:
NAPT
Web-based depression and distress monitoring application

Locations

Country Name City State
Canada University of Alberta Edmonton Alberta

Sponsors (1)

Lead Sponsor Collaborator
University of Alberta

Country where clinical trial is conducted

Canada, 

Outcome

Type Measure Description Time frame Safety issue
Primary Distress Thermometer Score NCCN Distress Thermometer Score 6 months
Secondary QIDS Score Quick Inventory of Depressive Symptomatology-Self Report (QIDS-SR) 6 and 12 months
Secondary HNRN-33 Head and Neck Research Network (HNRN-33) 6 and 12 months
Secondary Completion of Adjuvant Therapy Completion of Adjuvant Therapy, including radiation or chemotherapy 6 months
Secondary Return to work Return to work by 12 months 12 months
Secondary Hospital Readmissions Hospital Readmissions 12 months
Secondary Primary Care Visits Primary Care Visits to Family Physician 12 months
Secondary Emergency Department Visits Emergency Department Visits 12 months
See also
  Status Clinical Trial Phase
Not yet recruiting NCT05302583 - Aromatherapy Inhaler Use for HSCT Distress N/A